AstraZeneca PLC (LON:AZN) Receives £143.33 Consensus PT from Analysts

AstraZeneca PLC (LON:AZN) has received a consensus rating of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is £145.83.

A number of brokerages have recently commented on AZN. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research note on Thursday, January 15th. Citigroup assumed coverage on AstraZeneca in a research report on Tuesday, January 27th. They issued a “buy” rating and a £170 price objective on the stock. Shore Capital reaffirmed a “buy” rating on shares of AstraZeneca in a research note on Friday, January 16th. Jefferies Financial Group reiterated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research note on Monday, November 10th. Finally, Berenberg Bank raised their price target on shares of AstraZeneca from £145 to £160 and gave the company a “buy” rating in a research report on Tuesday, January 27th.

AstraZeneca Stock Down 1.5%

LON:AZN opened at £138.24 on Tuesday. AstraZeneca has a 1-year low of GBX 9,573.51 and a 1-year high of £144.10. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The firm has a market capitalization of £214.31 billion, a P/E ratio of 22.96, a PEG ratio of 0.86 and a beta of 0.17. The company’s fifty day moving average price is £137.60 and its 200-day moving average price is £126.42.

Insider Activity at AstraZeneca

In other news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was sold at an average price of £134.96, for a total transaction of £40,083.12. 0.14% of the stock is owned by company insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.